Journal
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
Volume 61, Issue 48, Pages -Publisher
WILEY-V C H VERLAG GMBH
DOI: 10.1002/anie.202206074
Keywords
F-19 MRI Imaging; Cancer Therapy; Ferroptosis; Hypoxia Resistance; O-2 Delivery
Categories
Funding
- National Natural Science Foundation of China [U21A20287, 51872088, 21890744, 21974039]
- Science and Technology Project of Hunan Province [2020RC3022, 2020SK2014]
- Shenzhen Science and Technology Program [JCYJ20210324140205013]
Ask authors/readers for more resources
In this study, a novel nanoplatform was designed to enhance the effectiveness of ferroptosis-based cancer therapy. The nanoplatform successfully overcame the hypoxia-induced resistance of ferroptosis by providing oxygen supply and breaking down lipid droplets. The results showed that the nanoplatform induced higher levels of oxidative stress, lipid peroxidation, and GSH depletion, leading to effective inhibition of tumor growth. Furthermore, the release of manganese from the nanoplatform could be monitored using imaging techniques.
Lipid peroxides accumulation induced ferroptosis is an effective cell death pathway for cancer therapy. However, the hypoxic condition of tumor microenvironment significantly suppresses the efficacy of ferroptosis. Here, we design a novel nanoplatform to overcome hypoxia-induced ferroptosis resistance. Specifically, we synthesize a novel kind of perfluorocarbon (PFOB)@manganese oxide (MnOx) core-shell nanoparticles (PM-CS NPs). Owing to the good carrier of O-2 as fuel, PM-CS NPs can induce higher level of ROS generation, lipid peroxidation and GSH depletion, as well as lower activity of GPX4, compared with MnOx NPs alone. Moreover, the supplement of O-2 can relieve tumor hypoxia to break down the storage of intracellular lipid droplets and increase expression of ACSL4 (a symbol for ferroptosis sensitivity). Furthermore, upon stimulus of GSH or acidity, PM-CS NPs exhibit the turn on F-19-MRI signal and activatable T-1/T-2-MRI contrast for correlating with the release of Mn. Finally, PM-CS NPs exert high cancer inhibition rate for ferroptosis based therapy via synergetic combination of O-2-mediated enhancement of key pathways of ferroptosis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available